Gene and cell therapy in in vivo experiments
| Treated animals (strain) | Sacrificed animals | Pretreatment | Therapeutic approach | H4 KO cell manipulation | AAV2/9_Lacz virus |
| 8 (Swiss nude) | 8 | CAL | Sham | − | − |
| 8 (Swiss nude) | 8 | CAL | Cell | GFP | − |
| 9 (Swiss nude) | 6 | CAL | Cell | GFP/miR669 | − |
| 10 (Swiss nude) | 8 | TA ctx | Sham | − | − |
| 11 (Swiss nude) | 8 | TA ctx | Cell | GFP | − |
| 12 (Swiss nude) | 6 | TA ctx | Cell | GFP/miR669 | − |
| 4 (Sgcb-null) | 4 | − | Gene | − | miR669 |
| 4 (Sgcb-null) | 4 | − | Gene | − | miRdsRed |
| 12 (Swiss wt) | 12 | TA ctx | Gene | − | miR669 |
| 12 (Swiss wt) | 12 | TA ctx | Gene | − | miRdsRed |
| 4 (Swiss wt) | 3 | TA ctx | Oligo | − | miR669q |
| 4 (Swiss wt) | 3 | TA ctx | Oligo | − | SCR miRNAs |
| Treated animals (strain) | Sacrificed animals | Pretreatment | Therapeutic approach | H4 KO cell manipulation | AAV2/9_Lacz virus |
| 8 (Swiss nude) | 8 | CAL | Sham | − | − |
| 8 (Swiss nude) | 8 | CAL | Cell | GFP | − |
| 9 (Swiss nude) | 6 | CAL | Cell | GFP/miR669 | − |
| 10 (Swiss nude) | 8 | TA ctx | Sham | − | − |
| 11 (Swiss nude) | 8 | TA ctx | Cell | GFP | − |
| 12 (Swiss nude) | 6 | TA ctx | Cell | GFP/miR669 | − |
| 4 (Sgcb-null) | 4 | − | Gene | − | miR669 |
| 4 (Sgcb-null) | 4 | − | Gene | − | miRdsRed |
| 12 (Swiss wt) | 12 | TA ctx | Gene | − | miR669 |
| 12 (Swiss wt) | 12 | TA ctx | Gene | − | miRdsRed |
| 4 (Swiss wt) | 3 | TA ctx | Oligo | − | miR669q |
| 4 (Swiss wt) | 3 | TA ctx | Oligo | − | SCR miRNAs |
CAL, coronary artery ligation; Oligo, oligonucleotide miRNA precursor from Applied Biosystems; SCR, scramble. Minus signs indicate absence of that specific treatment.